Transcept Pharmaceuticals (TSPT +9.8%) gets a big boost from U.S. regulators today after the FDA...

|By:, SA News Editor

Transcept Pharmaceuticals (TSPT +9.8%) gets a big boost from U.S. regulators today after the FDA declined to lower the recommended dose of it's Intermezzo prescription sleep aid because the drug's label already recommends a lower dosage for women than men because of their smaller average size. The agency said it believes the bedtime dose of Ambien, Edluar and Zolpimist should be reduced from 10 milligrams to 5 milligrams because the drugs can impair alertness and driving ability in some people the next morning.